NO832292L - Modifiserte merkede nukleotider og polynukleotider samt deres fremstilling, anvendelse og paavisning - Google Patents
Modifiserte merkede nukleotider og polynukleotider samt deres fremstilling, anvendelse og paavisningInfo
- Publication number
- NO832292L NO832292L NO832292A NO832292A NO832292L NO 832292 L NO832292 L NO 832292L NO 832292 A NO832292 A NO 832292A NO 832292 A NO832292 A NO 832292A NO 832292 L NO832292 L NO 832292L
- Authority
- NO
- Norway
- Prior art keywords
- attached
- compound
- sig
- nucleotide
- component
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 title claims description 208
- 102000040430 polynucleotide Human genes 0.000 title claims description 90
- 108091033319 polynucleotide Proteins 0.000 title claims description 90
- 239000002157 polynucleotide Substances 0.000 title claims description 87
- 238000002360 preparation method Methods 0.000 title description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 54
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 27
- 125000003729 nucleotide group Chemical group 0.000 claims description 239
- 108020004414 DNA Proteins 0.000 claims description 168
- 238000000034 method Methods 0.000 claims description 131
- 150000001875 compounds Chemical class 0.000 claims description 95
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 78
- 239000000126 substance Substances 0.000 claims description 59
- 150000007523 nucleic acids Chemical class 0.000 claims description 47
- 102000039446 nucleic acids Human genes 0.000 claims description 43
- 108020004707 nucleic acids Proteins 0.000 claims description 43
- 235000000346 sugar Nutrition 0.000 claims description 43
- 210000000349 chromosome Anatomy 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 32
- 229920001184 polypeptide Polymers 0.000 claims description 32
- 102000053602 DNA Human genes 0.000 claims description 31
- 102000004190 Enzymes Human genes 0.000 claims description 31
- 108090000790 Enzymes Proteins 0.000 claims description 31
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 30
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 27
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 26
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 19
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 18
- 108091034117 Oligonucleotide Proteins 0.000 claims description 17
- 229910052796 boron Inorganic materials 0.000 claims description 16
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 16
- 108091028664 Ribonucleotide Proteins 0.000 claims description 12
- 230000004807 localization Effects 0.000 claims description 12
- 239000002336 ribonucleotide Substances 0.000 claims description 12
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 12
- 229920002477 rna polymer Polymers 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 12
- 239000002523 lectin Substances 0.000 claims description 11
- 150000002772 monosaccharides Chemical group 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 10
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 10
- 239000002777 nucleoside Substances 0.000 claims description 10
- 229910052698 phosphorus Inorganic materials 0.000 claims description 10
- 230000002285 radioactive effect Effects 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 9
- 208000016361 genetic disease Diseases 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 229930024421 Adenine Natural products 0.000 claims description 8
- 108090001090 Lectins Proteins 0.000 claims description 8
- 102000004856 Lectins Human genes 0.000 claims description 8
- 229960000643 adenine Drugs 0.000 claims description 8
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 8
- 229940104302 cytosine Drugs 0.000 claims description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims description 6
- 239000005515 coenzyme Substances 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 108091008039 hormone receptors Proteins 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 102000023848 polysaccharide binding proteins Human genes 0.000 claims description 2
- 108091008395 polysaccharide binding proteins Proteins 0.000 claims description 2
- ZEPAXLPHESYSJU-UHFFFAOYSA-N 2,3,4,5,6,7,8-heptahydroxyoctanal Chemical compound OCC(O)C(O)C(O)C(O)C(O)C(O)C=O ZEPAXLPHESYSJU-UHFFFAOYSA-N 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 238000001879 gelation Methods 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 150000002386 heptoses Chemical class 0.000 claims 1
- 150000002402 hexoses Chemical class 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 150000002972 pentoses Chemical class 0.000 claims 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 150000003538 tetroses Chemical class 0.000 claims 1
- 150000003641 trioses Chemical class 0.000 claims 1
- 150000002500 ions Chemical class 0.000 abstract description 7
- 239000013522 chelant Substances 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 153
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 99
- 229960002685 biotin Drugs 0.000 description 80
- 239000011616 biotin Substances 0.000 description 80
- 239000000523 sample Substances 0.000 description 77
- 235000020958 biotin Nutrition 0.000 description 74
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 45
- 108010090804 Streptavidin Proteins 0.000 description 43
- 238000006243 chemical reaction Methods 0.000 description 42
- 238000001514 detection method Methods 0.000 description 40
- 239000000047 product Substances 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 229910001868 water Inorganic materials 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 238000009396 hybridization Methods 0.000 description 31
- 229940088598 enzyme Drugs 0.000 description 30
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
- 108090001008 Avidin Proteins 0.000 description 28
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000002585 base Substances 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 229920005654 Sephadex Polymers 0.000 description 21
- 239000012507 Sephadex™ Substances 0.000 description 21
- 239000000872 buffer Substances 0.000 description 21
- 239000000758 substrate Substances 0.000 description 21
- -1 deazapurine Chemical group 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 18
- 239000001226 triphosphate Substances 0.000 description 18
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- 239000010410 layer Substances 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 235000011178 triphosphate Nutrition 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 108010062580 Concanavalin A Proteins 0.000 description 14
- 238000002372 labelling Methods 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 229920002684 Sepharose Polymers 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 12
- 239000003298 DNA probe Substances 0.000 description 12
- 230000001745 anti-biotin effect Effects 0.000 description 12
- 125000004057 biotinyl group Chemical class [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 11
- 230000008020 evaporation Effects 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 10
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 10
- 102000014150 Interferons Human genes 0.000 description 10
- 108010050904 Interferons Proteins 0.000 description 10
- 229910021538 borax Inorganic materials 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 235000010339 sodium tetraborate Nutrition 0.000 description 10
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 10
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 10
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 10
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 9
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000007901 in situ hybridization Methods 0.000 description 9
- 229940079322 interferon Drugs 0.000 description 9
- 238000013507 mapping Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 8
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000000411 inducer Substances 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000001641 gel filtration chromatography Methods 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 229940100892 mercury compound Drugs 0.000 description 7
- 150000002731 mercury compounds Chemical class 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 6
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 6
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- 239000007974 sodium acetate buffer Substances 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 5
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 5
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 5
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 230000001744 histochemical effect Effects 0.000 description 5
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000005304 joining Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 5
- 210000003055 polytene chromosome Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- HKAVADYDPYUPRD-UHFFFAOYSA-N 1h-pyrazine-2-thione Chemical compound SC1=CN=CC=N1 HKAVADYDPYUPRD-UHFFFAOYSA-N 0.000 description 4
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 4
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 4
- QUVSFZCWYBQJJK-UHFFFAOYSA-N 7-(bromomethyl)benzo[a]anthracene Chemical compound C1=CC2=CC=CC=C2C2=C1C(CBr)=C(C=CC=C1)C1=C2 QUVSFZCWYBQJJK-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108091060296 Glucosylated DNA Proteins 0.000 description 4
- 102000008072 Lymphokines Human genes 0.000 description 4
- 108010074338 Lymphokines Proteins 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 241000186983 Streptomyces avidinii Species 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- IYKNGWWPNRDDHK-ONEGZZNKSA-N [[5-[2,4-dioxo-5-[(e)-3-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]prop-1-enyl]pyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)CC1N1C(=O)NC(=O)C(\C=C\CNC(=O)CCCCC2C3NC(=O)NC3CS2)=C1 IYKNGWWPNRDDHK-ONEGZZNKSA-N 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000002269 analeptic agent Substances 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 229910017052 cobalt Inorganic materials 0.000 description 4
- 239000010941 cobalt Substances 0.000 description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 4
- 230000009918 complex formation Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 230000031864 metaphase Effects 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 150000003230 pyrimidines Chemical class 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000002342 ribonucleoside Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- PCDQPRRSZKQHHS-XVFCMESISA-N CTP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-XVFCMESISA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000701533 Escherichia virus T4 Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010054278 Lac Repressors Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000276498 Pollachius virens Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000002067 Protein Subunits Human genes 0.000 description 3
- 108010001267 Protein Subunits Proteins 0.000 description 3
- 102000009572 RNA Polymerase II Human genes 0.000 description 3
- 108010009460 RNA Polymerase II Proteins 0.000 description 3
- 108020004518 RNA Probes Proteins 0.000 description 3
- 239000003391 RNA probe Substances 0.000 description 3
- 108020004487 Satellite DNA Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 208000002903 Thalassemia Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000002559 cytogenic effect Effects 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 239000005549 deoxyribonucleoside Substances 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 3
- 238000006872 enzymatic polymerization reaction Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 150000003212 purines Chemical class 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 3
- LZFNFLTVAMOOPJ-XMAYFYEJSA-N (3r,5r,6s)-2-(hydroxymethyl)-6-methylsulfanyloxane-3,4,5-triol Chemical compound CS[C@@H]1OC(CO)[C@H](O)C(O)[C@H]1O LZFNFLTVAMOOPJ-XMAYFYEJSA-N 0.000 description 2
- MVORBLZUGBSUNB-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidine-5-carbaldehyde Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=O)=C1 MVORBLZUGBSUNB-XLPZGREQSA-N 0.000 description 2
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 2
- OZMVAFPILSPXRM-RRKCRQDMSA-N 5-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(N)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 OZMVAFPILSPXRM-RRKCRQDMSA-N 0.000 description 2
- OHAMXGZMZZWRCA-UHFFFAOYSA-N 5-formyluracil Chemical compound OC1=NC=C(C=O)C(O)=N1 OHAMXGZMZZWRCA-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 2
- 108010006591 Apoenzymes Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 241000701832 Enterobacteria phage T3 Species 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000014450 RNA Polymerase III Human genes 0.000 description 2
- 108010078067 RNA Polymerase III Proteins 0.000 description 2
- 101710086015 RNA ligase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 108010090851 Simplexvirus DNA polymerase Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 231100000071 abnormal chromosome number Toxicity 0.000 description 2
- VRQIXCOIBHRSSE-UHFFFAOYSA-N acetic acid;prop-2-en-1-amine Chemical compound CC([O-])=O.[NH3+]CC=C VRQIXCOIBHRSSE-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 159000000009 barium salts Chemical class 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 150000004712 monophosphates Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002718 pyrimidine nucleoside Substances 0.000 description 2
- 108700022487 rRNA Genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 108010062513 snake venom phosphodiesterase I Proteins 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- MFEVGQHCNVXMER-UHFFFAOYSA-L 1,3,2$l^{2}-dioxaplumbetan-4-one Chemical compound [Pb+2].[O-]C([O-])=O MFEVGQHCNVXMER-UHFFFAOYSA-L 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical class CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- FJZRCDHFLPXKEK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidine-5-carbonitrile Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C#N)=C1 FJZRCDHFLPXKEK-XLPZGREQSA-N 0.000 description 1
- JTJAXTDUPYESRS-RRKCRQDMSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(1,1,2,2,3,3,4,4,4-nonafluorobutyl)pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)=C1 JTJAXTDUPYESRS-RRKCRQDMSA-N 0.000 description 1
- VWCUMTCXBIRRSG-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-2-methoxybenzene Chemical compound COC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 VWCUMTCXBIRRSG-UHFFFAOYSA-N 0.000 description 1
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- STMDPCBYJCIZOD-UHFFFAOYSA-N 2-(2,4-dinitroanilino)-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O STMDPCBYJCIZOD-UHFFFAOYSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 108020005097 23S Ribosomal RNA Proteins 0.000 description 1
- AKLOLDQYWQAREW-UHFFFAOYSA-N 3,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1 AKLOLDQYWQAREW-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- VRWNELWMABBYCK-UHFFFAOYSA-N 4-bromocyclohexane-1,2-diamine Chemical compound NC1CCC(Br)CC1N VRWNELWMABBYCK-UHFFFAOYSA-N 0.000 description 1
- RUKJCCIJLIMGEP-ONEGZZNKSA-N 4-dimethylaminocinnamaldehyde Chemical compound CN(C)C1=CC=C(\C=C\C=O)C=C1 RUKJCCIJLIMGEP-ONEGZZNKSA-N 0.000 description 1
- FERHGDYGOMEXLT-TURQNECASA-N 5-(3-aminoprop-1-enyl)-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C=CCN)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 FERHGDYGOMEXLT-TURQNECASA-N 0.000 description 1
- NMWWDVMJVFWRKK-WQYNNSOESA-N 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid hydrobromide Chemical compound Br.OC(=O)C(=N)CCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 NMWWDVMJVFWRKK-WQYNNSOESA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- UIJSURSVLVISBO-UBKIQSJTSA-N 5-hydroxy-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(O)=C1 UIJSURSVLVISBO-UBKIQSJTSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241001502050 Acis Species 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KTKRLMGQTGFWIU-UHFFFAOYSA-N ClC(Cl)=[S+]Cl Chemical compound ClC(Cl)=[S+]Cl KTKRLMGQTGFWIU-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 101710154303 Cyclic AMP receptor protein Proteins 0.000 description 1
- ZWIADYZPOWUWEW-UHFFFAOYSA-N Cytidine 5'-diphosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-UHFFFAOYSA-N 0.000 description 1
- PCDQPRRSZKQHHS-UHFFFAOYSA-N Cytidine 5'-triphosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-UHFFFAOYSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241001600125 Delftia acidovorans Species 0.000 description 1
- 108700001457 Deoxycytidylate hydroxymethylases Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
- 102100029075 Exonuclease 1 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910000003 Lead carbonate Inorganic materials 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010092494 Periplasmic binding proteins Proteins 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102000005583 Pyrin Human genes 0.000 description 1
- 108010059278 Pyrin Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010006873 Threonine Dehydratase Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- XOKJUSAYZUAMGJ-UHFFFAOYSA-N Toyocamycin Natural products C1=C(C#N)C=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O XOKJUSAYZUAMGJ-UHFFFAOYSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XPAOKCSHUNYPBS-XSBNNCSWSA-N [(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2r,3r,5s)-3-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl] hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)[C@@H](CO)C1 XPAOKCSHUNYPBS-XSBNNCSWSA-N 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 1
- YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000012637 allosteric effector Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- KFUJUTFTRXYQMG-UHFFFAOYSA-N bis[4-(dimethylamino)phenyl]methanethione Chemical compound C1=CC(N(C)C)=CC=C1C(=S)C1=CC=C(N(C)C)C=C1 KFUJUTFTRXYQMG-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000003681 chemical substitution reactions by method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- JBJSVEVEEGOEBZ-SCZZXKLOSA-N coenzyme B Chemical compound OP(=O)(O)O[C@H](C)[C@@H](C(O)=O)NC(=O)CCCCCCS JBJSVEVEEGOEBZ-SCZZXKLOSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- FMWMEQINULDRBI-UHFFFAOYSA-L copper;sulfite Chemical compound [Cu+2].[O-]S([O-])=O FMWMEQINULDRBI-UHFFFAOYSA-L 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- ZWIADYZPOWUWEW-ZAKLUEHWSA-N cytidine-5'-diphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO[P@](O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-ZAKLUEHWSA-N 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000014670 detection of bacterium Effects 0.000 description 1
- 230000023077 detection of light stimulus Effects 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000000659 freezing mixture Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- QTWZICCBKBYHDM-UHFFFAOYSA-N leucomethylene blue Chemical compound C1=C(N(C)C)C=C2SC3=CC(N(C)C)=CC=C3NC2=C1 QTWZICCBKBYHDM-UHFFFAOYSA-N 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 210000000415 mammalian chromosome Anatomy 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 1
- CSJDCSCTVDEHRN-UHFFFAOYSA-N methane;molecular oxygen Chemical compound C.O=O CSJDCSCTVDEHRN-UHFFFAOYSA-N 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- NCGWKCHAJOUDHQ-UHFFFAOYSA-N n,n-diethylethanamine;formic acid Chemical compound OC=O.OC=O.CCN(CC)CC NCGWKCHAJOUDHQ-UHFFFAOYSA-N 0.000 description 1
- XTAZYLNFDRKIHJ-UHFFFAOYSA-N n,n-dioctyloctan-1-amine Chemical class CCCCCCCCN(CCCCCCCC)CCCCCCCC XTAZYLNFDRKIHJ-UHFFFAOYSA-N 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 150000002940 palladium Chemical class 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- WRMXOVHLRUVREB-UHFFFAOYSA-N phosphono phosphate;tributylazanium Chemical compound OP(O)(=O)OP([O-])([O-])=O.CCCC[NH+](CCCC)CCCC.CCCC[NH+](CCCC)CCCC WRMXOVHLRUVREB-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- UCTSZMFEORYZAI-UHFFFAOYSA-M potassium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;phosphoric acid Chemical compound [K+].OP(O)([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O UCTSZMFEORYZAI-UHFFFAOYSA-M 0.000 description 1
- HJRIWDYVYNNCFY-UHFFFAOYSA-M potassium;dimethylarsinate Chemical compound [K+].C[As](C)([O-])=O HJRIWDYVYNNCFY-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical class C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- QXADHXQCAQTNGW-UHFFFAOYSA-M sodium;boric acid;hydroxide Chemical compound [OH-].[Na+].OB(O)O QXADHXQCAQTNGW-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002363 thiamine pyrophosphate Drugs 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 239000011678 thiamine pyrophosphate Substances 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- XOKJUSAYZUAMGJ-WOUKDFQISA-N toyocamycin Chemical compound C1=C(C#N)C=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O XOKJUSAYZUAMGJ-WOUKDFQISA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- JBFRIFLOBVAOCD-UHFFFAOYSA-N trioctylazanium;hydroxide Chemical compound [OH-].CCCCCCCC[NH+](CCCCCCCC)CCCCCCCC JBFRIFLOBVAOCD-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39144082A | 1982-06-23 | 1982-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO832292L true NO832292L (no) | 1983-12-27 |
Family
ID=23546604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO832292A NO832292L (no) | 1982-06-23 | 1983-06-23 | Modifiserte merkede nukleotider og polynukleotider samt deres fremstilling, anvendelse og paavisning |
Country Status (11)
Country | Link |
---|---|
US (2) | US8097405B1 (fr) |
EP (7) | EP0618228A1 (fr) |
JP (4) | JP2625095B2 (fr) |
AT (3) | ATE165605T1 (fr) |
AU (2) | AU585199B2 (fr) |
CA (1) | CA1223831A (fr) |
DE (3) | DE3382822T2 (fr) |
DK (1) | DK291183A (fr) |
ES (4) | ES8700270A1 (fr) |
IL (1) | IL69051A (fr) |
NO (1) | NO832292L (fr) |
Families Citing this family (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2540122B1 (fr) * | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
US4994373A (en) | 1983-01-27 | 1991-02-19 | Enzo Biochem, Inc. | Method and structures employing chemically-labelled polynucleotide probes |
CA1309672C (fr) * | 1983-01-27 | 1992-11-03 | Jannis G. Stavrianopoulos | Methodes et structures utilisant des sondes de polynucleotides nonradioactives marquees chimiquement |
US4948882A (en) * | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
CA1254525A (fr) * | 1983-04-13 | 1989-05-23 | Christine L. Brakel | Trousse pour le marquage chimique de l'adn en terminaison de chaine |
IL71699A0 (en) * | 1983-05-02 | 1984-07-31 | Enzo Biochem Inc | Methods and kits for the analysis and detection of biological or genetic material |
CA1228811A (fr) | 1983-05-05 | 1987-11-03 | Robert G. Pergolizzi | Methode d'analyse utilisant des sequences de polynucleotides |
EP0128018B1 (fr) * | 1983-05-31 | 1992-07-15 | Orgenics Ltd. | Sonde moléculaire génétique et méthode pour sa préparation, technique d'analyse et trousse utilisant cette sonde moléculaire génétique |
CA1338856C (fr) * | 1983-07-05 | 1997-01-21 | Jannis Stavrianopoulos | Marquage in vivo de sequences de polynucleotides |
IL73578A (en) * | 1983-12-12 | 1989-09-28 | Miles Lab | Method and reagent for the detection of polynucleotide sequence in sample of dna or rna by using a nucleic acid probe and contact of duplexes with immobilizing antibody |
EP0144914A3 (fr) * | 1983-12-12 | 1986-08-13 | Miles Inc. | Test d'hybridation utilisant des paires marquées de réactifs pouvant lier un hybride |
EP0146039A3 (fr) * | 1983-12-12 | 1986-08-27 | Miles Inc. | Test d'hybridation avec immobilisation d'hybrides par liaison antihybride |
US4777129A (en) * | 1983-12-12 | 1988-10-11 | Molecular Diagnostics, Inc. | Nucleic acid probe detectable by specific nucleic acid binding protein |
US4724202A (en) * | 1983-12-12 | 1988-02-09 | Molecular Diagnostics, Inc. | Use of non-hybridizable nucleic acids for the detection of nucleic acid hybridization |
USRE43096E1 (en) | 1984-01-16 | 2012-01-10 | California Institute Of Technology | Tagged extendable primers and extension products |
US4707440A (en) * | 1984-01-30 | 1987-11-17 | Enzo Biochem, Inc. | Nucleic acid hybridization assay and detectable molecules useful in such assay |
US4748111A (en) * | 1984-03-12 | 1988-05-31 | Molecular Diagnostics, Inc. | Nucleic acid-protein conjugate used in immunoassay |
CA1260372A (fr) * | 1984-04-27 | 1989-09-26 | Elazar Rabbani | Methode d'hybridation pour la detection de materiaux genetiques |
US4766064A (en) * | 1984-05-07 | 1988-08-23 | Allied Corporation | Displacement polynucleotide assay employing polyether and diagnostic kit |
US4766062A (en) * | 1984-05-07 | 1988-08-23 | Allied Corporation | Displacement polynucleotide assay method and polynucleotide complex reagent therefor |
CA1264451A (fr) * | 1984-05-23 | 1990-01-16 | Nanibhushan Dattagupta | Sonde d'acide nucleique couplee a un marqueur radioactif |
US4670380A (en) * | 1984-05-23 | 1987-06-02 | Molecular Diagnostics, Inc. | Assays utilizing labeled nucleic acid probes |
US4957858A (en) * | 1986-04-16 | 1990-09-18 | The Salk Instute For Biological Studies | Replicative RNA reporter systems |
IL71947A (en) * | 1984-05-29 | 1987-10-30 | Yeda Research And Dev Comp Ltd | Enzyme hydrazides and method for detection and determination of glycoconjugates |
FR2565996B1 (fr) * | 1984-06-15 | 1988-01-22 | Inst Nat Sante Rech Med | Acides nucleiques marques chimiquement, leur utilisation et necessaire pour sa mise en oeuvre |
DE3431536A1 (de) * | 1984-08-28 | 1986-03-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Derivatisierte nucleinsaeure-sequenz, verfahren zu deren herstellung sowie deren verwendung zum nachweis von nucleinsaeuren |
US4692509A (en) * | 1984-11-27 | 1987-09-08 | Molecular Diagnostics, Inc. | Radioactive labeling of proteins with nucleosides or nucleotides |
US4670379A (en) * | 1984-12-19 | 1987-06-02 | E. I. Du Pont De Nemours And Company | Polynucleotide hydridization assays employing catalyzed luminescence |
ATE43348T1 (de) * | 1985-01-24 | 1989-06-15 | Neopharmed Spa | Acylierte cytidin-diphosphat-choline, verfahren zu ihrer herstellung und ihre therapeutische verwendung. |
EP0198207B1 (fr) * | 1985-03-21 | 1989-12-20 | Molecular Diagnostics, Inc. | Ioduration spécifique d'acide nucléique |
US4767699A (en) * | 1985-05-02 | 1988-08-30 | Allied Corporation | Diagnostic reagent, kit and method employing polynucleotide displacement, separation, enzymatic cleavage and adenosine phosphate detection |
US5273882A (en) * | 1985-06-13 | 1993-12-28 | Amgen | Method and kit for performing nucleic acid hybridization assays |
EP0209996A3 (fr) * | 1985-06-25 | 1987-09-02 | Siska Diagnostics,Inc. | Sondes d'acides nucléiques renfermant des cytidines N4-(amino-substituées) |
US4780405A (en) * | 1985-06-25 | 1988-10-25 | Siska Diagnostics, Inc. | Carbonic anhydrase inhibitor-tagged nucleic acid probes |
US4833251A (en) * | 1985-06-25 | 1989-05-23 | Siska Diagnostics, Inc. | Compounds for tagging nucleic acid probes |
CA1295559C (fr) * | 1985-08-13 | 1992-02-11 | Jannis Stavrianopoulos | Methode d'etiquetage des sequences de polynucleotides |
JP2509574B2 (ja) * | 1985-08-15 | 1996-06-19 | アモコ・コーポレーション | 標識付けした核酸 |
JP3293820B2 (ja) * | 1985-12-13 | 2002-06-17 | エンゾ− バイオケム インコ−ポレイテツド | 標的ポリヌクレオチドにハイブリツド形成するための新規な一工程方法とポリヌクレオチド化合物 |
JPS638396A (ja) * | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
US6022958A (en) * | 1986-08-13 | 2000-02-08 | Bayer Corporation | cDNAs coding for members of the carcinoembryonic antigen family |
GB8621337D0 (en) * | 1986-09-04 | 1986-10-15 | Agricultural Genetics Co | Non-radioactive nucleic acid hybridization probes |
SE454781B (sv) * | 1986-10-17 | 1988-05-30 | Wallac Oy | Hybridiseringsforfarande for detektion av polynukleotidsekvens |
AU619170B2 (en) * | 1987-01-09 | 1992-01-23 | Abbott Laboratories | Diagnostic assays using nucleic acid probes |
US5057302A (en) * | 1987-02-13 | 1991-10-15 | Abbott Laboratories | Bifunctional chelating agents |
US5227474A (en) * | 1987-02-13 | 1993-07-13 | Abbott Laboratories | Bifunctional chelating agents |
AU622104B2 (en) * | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
AU623090B2 (en) * | 1987-07-31 | 1992-05-07 | Gen-Probe Incorporated | Assay for polynucleotides employing oligonucleotides to eliminate undesirable cross reactions |
GB2209754A (en) * | 1987-09-17 | 1989-05-24 | Thomas Lee Mattson | Polyaldehydic polynucleotides in use as probes,their preparation and use |
US5245026A (en) * | 1987-09-24 | 1993-09-14 | Abbott Laboratories | Metal containing 8-hydroxyquinoline chelating agents |
US5021567A (en) * | 1987-09-24 | 1991-06-04 | Abbott Laboratories | 8-hydroxyquinoline chelating agents |
US5525465A (en) * | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
EP0383803B1 (fr) * | 1987-10-28 | 2000-05-03 | Howard Florey Institute Of Experimental Physiology And Medicine | Conjugues d'oligonucleotide-polyamide |
US4886741A (en) * | 1987-12-09 | 1989-12-12 | Microprobe Corporation | Use of volume exclusion agents for the enhancement of in situ hybridization |
US5109124A (en) * | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US5047523A (en) * | 1988-08-02 | 1991-09-10 | Ortho Diagnostic Systems Inc. | Nucleic acid probe for detection of neisseria gonorrhoea |
US5185243A (en) * | 1988-08-25 | 1993-02-09 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
US5858652A (en) * | 1988-08-30 | 1999-01-12 | Abbott Laboratories | Detection and amplification of target nucleic acid sequences |
WO1990006670A2 (fr) * | 1988-12-07 | 1990-06-28 | The General Hospital Corporation | Procede d'enrichissement et de clonage pour adn contenant une insertion ou correspondant a une deletion |
US5324829A (en) * | 1988-12-16 | 1994-06-28 | Ortho Diagnostic Systems, Inc. | High specific activity nucleic acid probes having target recognition and signal generating moieties |
GR1000347B (el) * | 1988-12-21 | 1992-06-25 | Ortho Diagnostic Systems Inc | Μεθοδος παραγωγης νουκλεοτιδικων ανιχνευτων χρησιμοποιωντας ενα συμπληρωμα γεφυρωσεως. |
US5998135A (en) | 1989-02-24 | 1999-12-07 | Enzo Diagnostics, Inc. | Energy transfer hybridization assay using intercalators and lanthanide metals |
EP0385410B1 (fr) * | 1989-02-28 | 1996-10-02 | Canon Kabushiki Kaisha | Oligonucléotide à double brin partiel et son procédé de formation |
CA2012982A1 (fr) * | 1989-03-27 | 1990-09-27 | Frank W. Hobbs | Procede pour la detection rapide de l'acide nucleique par incorporation d'un groupe marqueur dans l'acide nucleique detecte par amplification de la cible |
DE3916871A1 (de) * | 1989-05-24 | 1990-11-29 | Boehringer Mannheim Gmbh | Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren |
EP0407816A3 (en) * | 1989-07-14 | 1993-01-27 | Abbott Laboratories | Base modified nucleosides |
DE4020529A1 (de) * | 1989-09-12 | 1991-03-21 | Roxana Vasiloiu | Multifunktionelle(s) enzym(e) mit nucleosid-didesoxyribosyltransferase(n) und/oder nucleoside-desoxyribosyltransferasen(n) und/oder kinease- und/oder reduktase- und/oder desaminase- und/oder polymerase-aktivitaet |
ATE193019T1 (de) * | 1989-10-13 | 2000-06-15 | Zeneca Ltd | Sonden |
WO1993024511A1 (fr) * | 1992-05-29 | 1993-12-09 | Howard Florey Institute Of Experimental Physiology And Medicine | Conjugues d'oligonucleotide-polyamide |
WO1991011533A1 (fr) * | 1990-01-26 | 1991-08-08 | E.I. Du Pont De Nemours And Company | Procede d'isolement de produits d'extension a partir de reactions de polymerase d'amorces d'adn orientees a l'aide d'un brin complementaire |
AU7759291A (en) * | 1990-03-29 | 1991-10-21 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
US5677440A (en) * | 1990-07-16 | 1997-10-14 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates |
US5612199A (en) * | 1991-10-11 | 1997-03-18 | Behringwerke Ag | Method for producing a polynucleotide for use in single primer amplification |
US5292938A (en) * | 1992-04-13 | 1994-03-08 | Associated Universities, Inc. | Synthesis of 4-substituted-trans-1, 2-diaminocyclohexyl polyaminocarboxylate metal chelating agents for the preparation of stable radiometal antibody immunoconjugates for therapy and spect and pet imaging |
WO1994003637A1 (fr) * | 1992-07-31 | 1994-02-17 | Syntex (Usa) Inc. | Procede d'introduction de sequences definies a l'extremite 3' de polynucleotides |
US5312527A (en) * | 1992-10-06 | 1994-05-17 | Concordia University | Voltammetric sequence-selective sensor for target polynucleotide sequences |
US5767259A (en) * | 1994-12-27 | 1998-06-16 | Naxcor | Oligonucleotides containing base-free linking groups with photoactivatable side chains |
US6495676B1 (en) | 1993-04-13 | 2002-12-17 | Naxcor | Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents |
US5616464A (en) * | 1994-12-27 | 1997-04-01 | Naxcor | Nucleic acid sequence detection employing amplification probes |
US6294323B1 (en) | 1993-04-14 | 2001-09-25 | Behringwerke Ag | Self initiating single primer amplification of nucleic acids |
US5925517A (en) * | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
US5446137B1 (en) * | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
CA2140081C (fr) * | 1994-01-13 | 2008-04-01 | Dean L. Engelhardt | Procede, construct et conjugue permettant de produire des copies multiples d'acides nucleiques |
US5731153A (en) * | 1996-08-26 | 1998-03-24 | The Regents Of The University Of California | Identification of random nucleic acid sequence aberrations using dual capture probes which hybridize to different chromosome regions |
US5783387A (en) * | 1995-02-06 | 1998-07-21 | The Regents Of The University Of California | Method for identifying and quantifying nucleic acid sequence aberrations |
US6027879A (en) * | 1995-08-09 | 2000-02-22 | The Regents Of The University Of California | Detection and isolation of nucleic acid sequences using a bifunctional hybridization probe |
US5616465A (en) * | 1995-08-09 | 1997-04-01 | The Regents Of The University Of California | Detection and isolation of nucleic acid sequences using competitive hybridization probes |
CA2279669A1 (fr) | 1995-12-15 | 1997-06-16 | Enzo Therapeutics, Inc. | Construits possedant certaines proprietes et/ou modifiant certaines proprietes pour l'expression de la transformation des composes d'acide nucleique allogenes pour utilisation therapeutique ou de diagnostique |
GB9602028D0 (en) | 1996-02-01 | 1996-04-03 | Amersham Int Plc | Nucleoside analogues |
JP3898228B2 (ja) * | 1996-04-12 | 2007-03-28 | ザ パブリック ヘルス リサーチ インスティチュート オブ ザ シティー オブ ニューヨーク インク | 検出プローブ、キット及びアッセイ |
JP2000514799A (ja) * | 1996-07-03 | 2000-11-07 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | オリゴヌクレオチドリンカーおよび固定化および結合オリゴヌクレオチドを用いる技術 |
CA2262019C (fr) | 1996-08-02 | 2011-11-15 | Bio Merieux | Procede d'amplification d'une sequence d'un acide nucleique cible |
ATE293123T1 (de) * | 1997-09-12 | 2005-04-15 | Exiqon As | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
DE19741715A1 (de) * | 1997-09-22 | 1999-03-25 | Hoechst Ag | Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung |
FR2780059B1 (fr) | 1998-06-17 | 2002-10-11 | Bio Merieux | Procede de marquage d'un acide ribonucleique et fragments d'arn marques ainsi obtenus |
US6037130A (en) * | 1998-07-28 | 2000-03-14 | The Public Health Institute Of The City Of New York, Inc. | Wavelength-shifting probes and primers and their use in assays and kits |
DE19850594A1 (de) * | 1998-11-03 | 2000-05-04 | Biochip Technologies Gmbh | Verfahren zur Markierung von Nukleinsäuren |
US6613516B1 (en) | 1999-10-30 | 2003-09-02 | Affymetrix, Inc. | Preparation of nucleic acid samples |
US6902891B2 (en) | 1999-12-17 | 2005-06-07 | Bio Merieux | Process for labeling a nucleic acid |
US6489114B2 (en) | 1999-12-17 | 2002-12-03 | Bio Merieux | Process for labeling a ribonucleic acid, and labeled RNA fragments which are obtained thereby |
AU782912B2 (en) | 1999-12-28 | 2005-09-08 | Association Francaise Contre Les Myopathies | Use of lithium (Li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
WO2001094609A1 (fr) * | 2000-06-07 | 2001-12-13 | Li-Cor, Inc. | Nucleotides a commutation de charges |
US7338805B2 (en) | 2001-05-04 | 2008-03-04 | Bio Merieux | Labeling reagents, methods for synthesizing such reagents and methods for detecting biological molecules |
US7060441B2 (en) | 2001-05-04 | 2006-06-13 | Biomerieux | Method for fragmenting and labeling DNA involving abasic sites and phosphate labeling |
FR2827304B1 (fr) * | 2001-07-16 | 2004-05-21 | Commissariat Energie Atomique | Procede et support d'analyse biologique utilisant des oligonucleotides comportant un marqueur activable enzymatiquement |
US20070136825A1 (en) | 2001-09-18 | 2007-06-14 | Wolf-Bernd Frommer | Fusion proteins useful for detecting analytes |
DE602004026173D1 (de) | 2003-04-29 | 2010-05-06 | Gen Hospital Corp | Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln |
AU2004263274B2 (en) | 2003-07-21 | 2009-11-05 | Transgene S.A. | Novel multifunctional cytokines |
US7459021B2 (en) | 2003-09-03 | 2008-12-02 | Shmuel Bukshpan | Methods and apparatus for rapid crystallization of biomolecules |
JP3615752B1 (ja) | 2003-11-18 | 2005-02-02 | 淳 高橋 | 細径樹脂捩じりブラシ |
US7022492B2 (en) | 2003-12-15 | 2006-04-04 | Dade Behring Inc. | Ecstasy haptens and immunogens |
US6991911B2 (en) | 2003-12-15 | 2006-01-31 | Dade Behring Inc. | Assay for entactogens |
FR2868071B1 (fr) | 2004-03-26 | 2006-06-09 | Biomerieux Sa | Reactifs de marquage, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques |
WO2006032436A2 (fr) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag. | Utilisation de microproteines en tant qu'inhibiteurs d'une tryptase |
US7541144B2 (en) * | 2005-01-31 | 2009-06-02 | Agilent Technologies, Inc. | RNA labeling method |
ATE468406T1 (de) | 2005-02-02 | 2010-06-15 | Univ Bayreuth | Esterasen zur überwachung der proteinbiosynthese in vitro |
FR2886735B1 (fr) | 2005-06-01 | 2015-09-11 | Biomerieux Sa | Procede de marquage ou de traitement d'un echantillon biologique contenant des molecules biologiques d'interet, notamment des acides nucleiques |
US8076064B2 (en) * | 2005-07-09 | 2011-12-13 | Agilent Technologies, Inc. | Method of treatment of RNA sample |
US7718365B2 (en) * | 2005-07-09 | 2010-05-18 | Agilent Technologies, Inc. | Microarray analysis of RNA |
US7544471B2 (en) * | 2005-07-30 | 2009-06-09 | Agilent Technologies, Inc. | Preparing RNA from a wax-embedded tissue specimen |
ES2436404T3 (es) | 2005-10-03 | 2013-12-30 | University Health Network | Inhibidores ODCasa para el tratamiento de malaria |
US7700289B2 (en) * | 2006-04-03 | 2010-04-20 | Agilent Technologies, Inc. | Method for labeling RNA |
US8647119B1 (en) | 2006-04-18 | 2014-02-11 | President And Fellows Of Harvard College | Methods and kits with fluorescent probes for caries detection |
US20080038686A1 (en) * | 2006-04-18 | 2008-02-14 | Shigemi Nagai | Methods and kits for early stage caries detection |
US8129115B2 (en) | 2006-06-06 | 2012-03-06 | Panasonic Corporation | Method of modifying nucleotide chain |
US7772390B1 (en) | 2006-07-18 | 2010-08-10 | The Regents Of The University Of California | Lipid mediated nucleic acid synthesis |
US20080091005A1 (en) * | 2006-07-20 | 2008-04-17 | Visigen Biotechnologies, Inc. | Modified nucleotides, methods for making and using same |
WO2008092854A2 (fr) | 2007-01-30 | 2008-08-07 | Transgene S.A. | Vaccin contre le papillomavirus |
FR2917090B1 (fr) | 2007-06-11 | 2012-06-15 | Biomerieux Sa | Reactifs de marquage portant des fonctions diazo et nitro, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques |
SI2197900T1 (sl) | 2007-08-24 | 2012-11-30 | Julius Maximilians Uni Wurzburg | Mutantni dvojno ciklizirani receptorski peptidi ki inhibirajo protitelesa beta adrenoceptorja |
FR2934595B1 (fr) | 2008-07-29 | 2013-04-05 | Biomerieux Sa | Reactifs de marquage ayant un noyau pyridine portant une fonction diazomethyle, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques |
GB0815968D0 (en) * | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
US20120087870A1 (en) | 2008-12-19 | 2012-04-12 | Hentges Francois | Novel caviidae allergens and uses thereof |
US20110312872A1 (en) | 2008-12-22 | 2011-12-22 | Universität Regensburg | Norrin in the treatment of diseases associated with an increased tgf-beta activity |
US20120034650A1 (en) | 2009-02-13 | 2012-02-09 | Novartis Ag | Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof |
DE102010018878B4 (de) | 2009-04-30 | 2013-09-26 | Julius-Maximilians-Universität Würzburg | Neue Zell-Linie zur Fluoreszenz-basierten Detektion von funktionell aktiven Antikörpern und Autoantikörpern gegen den Beta1-adrenergen Rezeptor |
CA2770075C (fr) | 2009-08-07 | 2021-08-24 | Perrine Martin | Composition pour le traitement d'une infection par le virus de l'hepatite b |
WO2011023764A1 (fr) | 2009-08-26 | 2011-03-03 | Medizinische Hochschule Hannover | Moyens et méthodes pour la production de polysaccharides capsulaires artificiels de neisseria meningitidis |
BR112012016233A2 (pt) * | 2009-12-31 | 2017-03-07 | Ventana Med Syst Inc | métodos para produzir uma sonda de ácido nucleico, sonda de ácido nucleico isolado e kit |
US9320756B2 (en) | 2010-05-07 | 2016-04-26 | Centre National De La Recherche Scientifique | UCP1 (thermogenin)—inducing agents for use in the treatment of a disorder of the energy homeostasis |
CA2800018C (fr) | 2010-05-21 | 2021-09-28 | Universitaet Fuer Bodenkultur Wien | Compositions destinees a etre utilisees dans le traitement ou le diagnostic de troubles osseux et/ou de troubles cardiovasculaires |
EP2576617B1 (fr) | 2010-06-04 | 2016-04-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | ANTICORPS MONOCLONAUX CIBLANT DES OLIGOMÈRES Aß |
CA2802635A1 (fr) | 2010-06-18 | 2011-12-22 | Xiberscience Gmbh | Peptides en tant qu'agents actifs pour stabiliser des barrieres biologiques |
BR112013004358A2 (pt) | 2010-08-26 | 2017-06-27 | Center Leon Berard Centre Regional De Lutte Contre Le Cancer | proteína de fusão-dcc, molécula de ácido nucleico, vetor, célula hospedeira, método para produzir a proteína de fusão-dcc, proteína de fusão-dcc, composição farmacêutica, uso e método de tratamento do câncer em um sujeito pela administração da proteína de fusão-dcc. |
FR2968302B1 (fr) | 2010-12-06 | 2012-11-30 | Biomerieux Sa | Procedes de fonctionalisation et reactifs utilises dans de tels procedes utilisant un anhydride isatoique ou un de ses derives, molecules biologiques ainsi traitees et kits |
WO2012095841A1 (fr) | 2011-01-10 | 2012-07-19 | State Of Israel, Ministry Of Agriculture And Rural Development, A.R.O. - Volcani Center | Plants de tomate améliorés |
WO2012113779A1 (fr) | 2011-02-21 | 2012-08-30 | Medizinische Universität Wien | Moyens et procédés pour traiter une maladie ou un trouble relatif à la lymphangiogenèse ou prévenir la métastase |
EP2522689A1 (fr) | 2011-05-13 | 2012-11-14 | Universität Bayreuth | Non-viral transfection systems |
EP2523002A1 (fr) | 2011-05-13 | 2012-11-14 | Universität Bayreuth | Utilization of magnetic nanoparticles as intracellular pull-down system |
WO2013017656A1 (fr) | 2011-08-02 | 2013-02-07 | Medizinische Universität Wien | Antagonistes de ribonucléases pour traiter l'obésité |
WO2013024173A1 (fr) | 2011-08-17 | 2013-02-21 | Technische Universität München | Procédé mis en œuvre par ordinateur pour l'indentification de régions régulatrices ou de variations régulatrices |
RU2014129918A (ru) | 2011-12-22 | 2016-02-10 | Медицинише Универзитет Виен | Циклотиды в качестве иммунодепрессантов |
EP2626066A1 (fr) | 2012-02-10 | 2013-08-14 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Polythérapie comprenant des inhibiteurs VEGFR-2 sélectifs et inhibiteurs MEK |
CN104520312B (zh) | 2012-02-29 | 2017-12-19 | 先正达参股股份有限公司 | 种子活力的调节 |
EP2866821B1 (fr) | 2012-07-02 | 2018-11-14 | Medizinische Universität Wien | Produit de séparation du complément c4d pour le traitement d'affections inflammatoires |
MX359669B (es) | 2012-07-04 | 2018-10-05 | Wintershall Holding GmbH | Microorganismos modificados genéticamente capaces de producir beta-glucanos, y métodos para la producción de beta-glucanos. |
FR2994184B1 (fr) | 2012-08-02 | 2017-12-08 | Biomerieux Sa | Procedes de fonctionalisation et reactifs utilises dans de tels procedes utilisant un anhydride aza-isatoique ou un de ses derives, molecules biologiques ainsi traitees et kits |
EP2695950A1 (fr) | 2012-08-10 | 2014-02-12 | Blackfield AG | Marqueurs pour la réactivité à un inhibiteur du récepteur du facteur de croissance des fibroblastes |
EP2708241A1 (fr) | 2012-09-12 | 2014-03-19 | Netris Pharma | Protéine de fusion Fc de recombinaison des deux domaines d'immunoglobuline de UNC5 |
US10752945B2 (en) | 2012-09-12 | 2020-08-25 | The Regents Of The University Of California | Accurate genome sequencing of single cells by single-stranded amplification and sequencing |
EP2708231A1 (fr) | 2012-09-12 | 2014-03-19 | Netris Pharma | Traitement combiné de médicament interférant netrin-1 et médicament chimiothérapeutique |
US10203338B2 (en) | 2013-05-14 | 2019-02-12 | Siemens Healthcare Diagnostics Inc. | Stabilized liquid formulations containing receptors |
BR112015032225B1 (pt) | 2013-06-28 | 2022-05-17 | Ethris Gmbh | Composição, composição farmacêutica, uso de uma composição, e, método in vitro para dispensação de rna de fita simples a uma célula alvo ou tecido |
WO2015022326A1 (fr) | 2013-08-12 | 2015-02-19 | Xiber Science Gmbh | Peptides en tant qu'agents actifs pour le traitement d'un dysfonctionnement du greffon primaire |
MX348980B (es) | 2013-09-16 | 2017-07-05 | Cemm-Forschungszentrum Für Molekulare Medizin Gmbh | Calreticulina mutante para la diagnosis de malignidades mieloides. |
WO2015088990A1 (fr) | 2013-12-09 | 2015-06-18 | Durect Corporation | Complexes de principes pharmaceutiquement actifs, complexes de polymères, et compositions et procédés les impliquant |
US10532083B2 (en) | 2014-02-13 | 2020-01-14 | Technische Universität München | Methods for inducing differentiation or conversion of white adipocytes and/or preadipocytes to brown adipocites using FGF8 |
CN106414749A (zh) | 2014-02-26 | 2017-02-15 | 埃泽瑞斯公司 | 用于胃肠给予rna的组合物 |
WO2015158898A2 (fr) | 2014-04-17 | 2015-10-22 | Medizinische Hochschule Hannover | Moyens et méthodes de production de polysaccharides capsulaires de neisseria meningitidis de faible dispersité |
KR20170061693A (ko) | 2014-09-30 | 2017-06-05 | 바스프 에스이 | 적은 아크릴산을 갖는 아미드 화합물의 제조를 위한 수단 및 방법 |
US10227621B2 (en) | 2014-09-30 | 2019-03-12 | Basf Se | Method for preparing an aqueous acrylamide solution having a low acrylic acid concentration |
WO2016050819A1 (fr) | 2014-09-30 | 2016-04-07 | Basf Se | Procédé de préparation d'une solution d'acrylamide ayant une faible concentration d'acide acrylique |
EP3034539A1 (fr) | 2014-12-19 | 2016-06-22 | Ethris GmbH | Compositions pour l'introduction d'acides nucléiques dans des cellules |
EP3225694A1 (fr) | 2016-03-29 | 2017-10-04 | Basf Se | Procédé de production d'acrylamide par addition définie du biocatalyseur |
EP3225693A1 (fr) | 2016-03-29 | 2017-10-04 | Basf Se | Procédé de préparation de solutions d'acrylamide aqueuses |
KR102486471B1 (ko) | 2016-03-29 | 2023-01-10 | 바스프 에스이 | 증가된 점도를 갖는 폴리아크릴아미드 용액을 제조하는 방법 |
WO2017178193A1 (fr) | 2016-04-14 | 2017-10-19 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Procédé d'identification de séquences polynucléotidiques ou polypeptidiques aléatoires à activité biologique |
CN109153748A (zh) | 2016-04-26 | 2019-01-04 | 巴斯夫欧洲公司 | 制备聚丙烯酰胺水溶液的方法 |
WO2017186685A1 (fr) | 2016-04-26 | 2017-11-02 | Basf Se | Procédé de préparation d'une solution aqueuse de polyacrylamide |
AU2017257205A1 (en) | 2016-04-26 | 2018-10-18 | Basf Se | Method for preparing an aqueous polyacrylamide solution |
MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
WO2018185222A1 (fr) | 2017-04-05 | 2018-10-11 | Acib Gmbh - Austrian Centre Of Industrial Biotechnology | Aminoacyl-arnt synthétases et arnt orthogonaux |
US20210085756A1 (en) | 2017-07-26 | 2021-03-25 | Medizinische Universität Wien | Superactive mutant thymidine kinase for use in cancer therapy |
KR102431353B1 (ko) | 2017-10-16 | 2022-08-10 | 에프. 호프만-라 로슈 아게 | B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자 |
EP3740491A1 (fr) * | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Composés de pyrrolo[2,3-d]pyrimidines substitués utilisés en tant qu'inhibiteurs de la kinase ret |
BR112020021054A2 (pt) | 2018-04-25 | 2021-02-17 | Ethris Gmbh | composição, processo para a preparação de uma composição, e, composições sólida e para uso |
EP3807415A1 (fr) | 2018-06-13 | 2021-04-21 | Engenes Biotech GmbH | Synthèse d'analogue de la méthionine |
JP7102557B2 (ja) | 2018-07-03 | 2022-07-19 | エフ.ホフマン-ラ ロシュ アーゲー | Tau発現調節用オリゴヌクレオチド |
US20210332336A1 (en) | 2018-08-31 | 2021-10-28 | Leibniz-Institut Für Pflanzenbiochemie | Calcium dependent protein kinase constructs and uses thereof |
CN112654705B (zh) | 2018-09-11 | 2024-07-02 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) | 用在治疗代谢疾病中的微小rna抑制剂 |
WO2020070325A1 (fr) | 2018-10-05 | 2020-04-09 | Multiplex Dx | Procédé de diagnostic de maladies par fluorescence et séquençage multiplex |
RU2734941C2 (ru) * | 2018-12-19 | 2020-10-26 | Общество с ограниченной ответственностью "ИБМХ-ЭкоБиоФарм" (ООО "ИБМХ-ЭкоБиоФарм") | Способ получения модифицированных комбинаторных ДНК библиотек методом твердофазной реакции удлинения праймера на ПЭТ-микрочастицах |
EP4031658A1 (fr) | 2019-08-07 | 2022-07-27 | DB Biotech, AS | Polypeptides de peroxydase de raifort améliorés |
US20220332799A1 (en) | 2019-09-04 | 2022-10-20 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Herv inhibitors for use in treating tauopathies |
WO2021048257A1 (fr) | 2019-09-11 | 2021-03-18 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Vecteurs de phage bactéricides |
WO2021089584A1 (fr) | 2019-11-05 | 2021-05-14 | Basf Se | Procédé de stockage d'un biocatalyseur |
CN115697371A (zh) | 2020-03-20 | 2023-02-03 | 维也纳医科大学 | 大环寡肽与κ阿片样物质受体配体组合用于MS疗法 |
US20230175081A1 (en) | 2020-05-04 | 2023-06-08 | MultiplexDX, s.r.o. | Means and methods for detecting novel coronavirus (sars-cov-2) |
US20230287383A1 (en) | 2020-07-03 | 2023-09-14 | Engenes Biotech Gmbh | PYRROLYSYL-tRNA SYNTHETASE VARIANTS AND USES THEREOF |
CA3193353A1 (fr) | 2020-09-24 | 2022-03-31 | Carina WEHNER | Recepteurs de lymphocytes t specifiques de prame et leurs utilisations |
EP4119581A1 (fr) | 2021-07-14 | 2023-01-18 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Nouveaux dimères fab |
JP7386271B2 (ja) | 2022-01-21 | 2023-11-24 | 本田技研工業株式会社 | カムシャフト製造装置 |
EP4215042A1 (fr) | 2022-01-21 | 2023-07-26 | Max-Delbrück-Centrum für Molekulare Medizin | Mammifère non humain comprenant dans son génome au moins deux allèles d'antigène leucocytaire humain (hla) de classe ii, procédés de formation d'un tel mammifère et ses utilisations |
EP4299753A1 (fr) | 2022-06-29 | 2024-01-03 | enGenes Biotech GmbH | Procédé de production d'acides nucléiques extrachromosomiques |
WO2024003799A1 (fr) | 2022-06-29 | 2024-01-04 | Takeda Pharmaceutical Company Limited | Procédé de production d'acides nucléiques extrachromosomiques |
WO2024047155A1 (fr) | 2022-08-31 | 2024-03-07 | Dsm Ip Assets B.V. | Souches de bifidobacterium adolescentis, procédés et utilisations de celles-ci pour la dégradation de l'amidon et la modification de la flore intestinale chez des mammifères non humains |
WO2024089180A1 (fr) | 2022-10-26 | 2024-05-02 | Eximmium Biotechnologies Gmbh | Procédé de détermination de récupération de vésicule extracellulaire |
WO2024115430A1 (fr) | 2022-11-28 | 2024-06-06 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Phages acinetobacter baumannii |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1617886A1 (de) | 1967-03-06 | 1971-01-28 | Dr Med Karl Theurer | Verfahren zur Herstellung von Arzneimitteln mit selektivem Tropismus gegen Krebs und bestimmte Organe |
DE1814134A1 (de) | 1968-12-12 | 1970-09-10 | Theurer Dr Med Karl | Zusatzverfahren zur Herstellung von arzneimitteln mit selektivem Tropismus |
US3906031A (en) | 1971-03-15 | 1975-09-16 | Research Corp | Novel 9-fluorenylmethoxycarbonyl compounds |
US4124702A (en) | 1971-07-06 | 1978-11-07 | Merck & Co., Inc. | Polynucleotides active as inducers of interferon production in living animal cells |
US3931397A (en) | 1971-11-05 | 1976-01-06 | Beecham Group Limited | Biologically active material |
US3960840A (en) * | 1972-12-29 | 1976-06-01 | University Of Illinois Foundaton | Fluorescent derivatives of adenine-containing compounds |
JPS49126395A (fr) | 1973-04-04 | 1974-12-03 | ||
US4038480A (en) | 1973-09-17 | 1977-07-26 | Icn Pharmaceuticals, Inc. | 6-aminocarbonyl purine 3',5'-cyclic nucleotides |
GB1446536A (en) | 1975-02-21 | 1976-08-18 | Yeda Res & Dev | Pharmaceutically active compositions |
US4230797A (en) * | 1975-04-28 | 1980-10-28 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a coenzyme as label |
IN142734B (fr) * | 1975-04-28 | 1977-08-20 | Miles Lab | |
JPS53133283A (en) | 1977-04-25 | 1978-11-20 | Agency Of Ind Science & Technol | High polymers bonded to adenine nucleotide derivatives |
US4119521A (en) | 1977-04-25 | 1978-10-10 | Stephen Turner | Fluorescent derivatives of activated polysaccharides |
SU659573A1 (ru) * | 1977-05-31 | 1979-04-30 | Институт биологической физики АН СССР | Спин-меченые производные олигорибонуклеотидов как спиновые зонды дл исследовани механизма действи ферментов и способ их получени |
US4847240A (en) | 1978-01-16 | 1989-07-11 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
US4151065A (en) | 1978-01-30 | 1979-04-24 | The Regents Of The University Of California | Horizontal slab gel electrophoresis |
FR2422956A1 (fr) * | 1978-04-13 | 1979-11-09 | Pasteur Institut | Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede |
US4213893A (en) | 1978-10-12 | 1980-07-22 | Miles Laboratories, Inc. | Flavin adenine dinucleotide-labeled conjugates for use in specific binding assays |
IL57571A (en) * | 1978-06-22 | 1983-03-31 | Miles Lab | Flavin adenine dinucleotide-labeled conjugates and their use in a homogeneous immunoassay method for determining haptens |
JPS5519239A (en) | 1978-07-28 | 1980-02-09 | Green Cross Corp:The | Interferon-producing attractant |
DE2841414C2 (de) | 1978-09-22 | 1980-04-03 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf), 3300 Braunschweig | Verfahren zur Herstellung von an Makromoleküle gebundenen, ein Adeninringsystem enthaltenden Koenzymen |
US4305922A (en) * | 1978-10-04 | 1981-12-15 | University Patents, Inc. | Labeling proteins with 99m-Tc by ligand exchange |
JPS5564599A (en) | 1978-11-08 | 1980-05-15 | Unitika Ltd | Adenosine triphosphate derivative |
US4224408A (en) * | 1978-11-22 | 1980-09-23 | Abbott Laboratories | Deoxyribonucleic acid synthesis using binding protein |
US4260737A (en) * | 1979-03-16 | 1981-04-07 | University Patents, Inc. | Radioiodine labeling during protein synthesis |
DE3060377D1 (en) * | 1979-08-29 | 1982-07-01 | Nihon Mediphysics Co Ltd | 2-oxopropionaldehyde bis(thiosemicarbazone)derivatives and their production and use |
US4318846A (en) | 1979-09-07 | 1982-03-09 | Syva Company | Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers |
US4259232A (en) | 1979-10-23 | 1981-03-31 | Miles Laboratories, Inc. | Flavin adenine dinucleotide-labeled protein and polypeptide conjugates |
US4310662A (en) * | 1979-12-26 | 1982-01-12 | Genentech, Inc. | Nucleosidic phosphorylating agent and methods |
US4255566A (en) * | 1980-02-19 | 1981-03-10 | Miles Laboratories | Flavin adenine dinucleotide derivatives and labeled conjugates prepared therefrom |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4293310A (en) | 1980-03-14 | 1981-10-06 | University Of Pittsburgh | Photoelectrochemical immunoassay |
US4421735A (en) * | 1980-04-17 | 1983-12-20 | The Massachusetts General Hospital | Radiolabeled diagnostic compositions and method for making the same |
JPS5711999A (en) | 1980-06-26 | 1982-01-21 | Chugai Pharmaceut Co Ltd | Novel adenosine phosphate compound containing introduced iodine and its preparation |
JPS5742632A (en) | 1980-08-29 | 1982-03-10 | Takeshi Sasaki | Double-chain dna bonded to d-glutamic acid-d-lysine copolymer, its preparation and medicine containing the same |
US4358535A (en) * | 1980-12-08 | 1982-11-09 | Board Of Regents Of The University Of Washington | Specific DNA probes in diagnostic microbiology |
US4534647A (en) | 1981-02-23 | 1985-08-13 | Institut Molekulyarnoi Biologii Biokhimii Akademii Nauk Kazakhskoi SSR | Apparatus for photometrically scanning gels |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4529796A (en) * | 1981-03-30 | 1985-07-16 | Baker Instruments Corporation | Method for making chromogenic and/or fluorogenic substrates for use in monitoring catalytic or enzymatic activity |
US4378458A (en) * | 1981-03-30 | 1983-03-29 | Baker Instruments Corporation | Novel chromogenic and/or fluorogenic substrates for monitoring catalytic or enzymatic activity |
CA1194862A (fr) * | 1981-03-30 | 1985-10-08 | Jemo Kang | Methode de production de substrats chromogenes ou fluorogenes pour le controle de l'activite catalytique ou enzymatique |
US4708935A (en) | 1981-04-10 | 1987-11-24 | Research Corporation | (2-5')-Oligo (3'-deoxyadenylate) and derivatives thereof |
US4711955A (en) * | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
CA1219824A (fr) * | 1981-04-17 | 1987-03-31 | David C. Ward | Nucleotides modifies, leur preparation et leur emploi |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4375401A (en) | 1981-05-20 | 1983-03-01 | Nicholas Catsimpoolas | Electrophoresis system |
CA1205028A (fr) | 1981-07-01 | 1986-05-27 | Jerald C. Hinshaw | Chelates fluorescents et reactifs de liaison specifique marques prepares a partir desdits chelates |
CA1180647A (fr) | 1981-07-17 | 1985-01-08 | Cavit Akin | Methode de diagnostic d'hybridation de polynucleotides par emission de lumiere |
US4460772A (en) | 1981-08-27 | 1984-07-17 | Miles Laboratories, Inc. | 6-[N-(ω-Carboxyalkyl)amino]-1,3-dimethyl-5-formamidouracils |
CA1222691A (fr) * | 1981-12-29 | 1987-06-09 | Wilhelmus T. Goedemans | Methode de preparation de proteines marquees par un radionucleide, notamment des anticorps ou des fragments d'anticorps |
FR2519005B1 (fr) * | 1981-12-29 | 1985-10-25 | Pasteur Institut | Fragments d'adn marques a l'une au moins de leurs extremites par des ribonucleotides modifies reconnaissables par des molecules affines et procede pour realiser une analyse de tels fragments d'adn |
FR2519004B1 (fr) * | 1981-12-29 | 1985-09-27 | Pasteur Institut | Acide adenosine 5'-triphosphorique modifie et procede de dosage de substances biologiques susceptibles de fixer des produits de degradation de l'acide adenosine 5'-triphosphorique |
ATE53862T1 (de) * | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
EP0090789A1 (fr) | 1982-03-26 | 1983-10-05 | Monsanto Company | Synthèse chimique de DNA |
US4474948A (en) | 1982-04-08 | 1984-10-02 | Biosearch | Benzazolides and their employment in phosphite ester oligonucleotide synthesis processes |
US4490472A (en) | 1982-06-17 | 1984-12-25 | Imreg, Inc. | Sensitive tests for malignancies based on DNA detection |
US5241060A (en) * | 1982-06-23 | 1993-08-31 | Enzo Diagnostics, Inc. | Base moiety-labeled detectable nucleatide |
US5260433A (en) * | 1982-06-23 | 1993-11-09 | Enzo Diagnostics, Inc. | Saccharide specific binding system labeled nucleotides |
US4880918A (en) | 1982-07-13 | 1989-11-14 | Eliezer Rapaport | Arrest and killing of tumor cells by adenosine 5-diphosphate and adenosine-5-triphosphate |
JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
JPS5944648A (ja) | 1982-09-07 | 1984-03-13 | Sansou Seisakusho:Kk | デオキシリボ核酸の塩基配列決定方法 |
JPS59126252A (ja) | 1983-01-08 | 1984-07-20 | Fuji Photo Film Co Ltd | Dnaもしくはdna部分分解物の塩基配列決定法 |
US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
US4948882A (en) * | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4483964A (en) | 1983-06-20 | 1984-11-20 | Chiron Corporation | Reactor system and method for polynucleotide synthesis |
US4517338A (en) | 1983-06-20 | 1985-05-14 | Chiron Corporation | Multiple reactor system and method for polynucleotide synthesis |
US4598049A (en) | 1983-08-31 | 1986-07-01 | Systec Inc. | General purpose gene synthesizer |
JPS5993100A (ja) | 1983-10-31 | 1984-05-29 | Wakunaga Seiyaku Kk | オリゴヌクレオチド誘導体 |
JPS6096610A (ja) | 1983-10-31 | 1985-05-30 | Agency Of Ind Science & Technol | ニコチンアミド−アデニン−ジヌクレオチドホスフエ−トを結合した高分子物質 |
US4849513A (en) | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
US5015733A (en) | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
CA1244786A (fr) | 1983-12-20 | 1988-11-15 | Lloyd M. Smith | Syntese d'oligonucleotides |
US5171534A (en) | 1984-01-16 | 1992-12-15 | California Institute Of Technology | Automated DNA sequencing technique |
US4707440A (en) | 1984-01-30 | 1987-11-17 | Enzo Biochem, Inc. | Nucleic acid hybridization assay and detectable molecules useful in such assay |
JPH0610665B2 (ja) | 1984-02-01 | 1994-02-09 | 株式会社日立製作所 | 核酸の塩基配列決定装置 |
JPS60169495A (ja) | 1984-02-15 | 1985-09-02 | Takeda Chem Ind Ltd | 変性されたdνaおよびその用途 |
JPS60242368A (ja) | 1984-05-16 | 1985-12-02 | Hitachi Ltd | 核酸塩基配列決定方法 |
FR2568254B1 (fr) | 1984-07-25 | 1988-04-29 | Centre Nat Rech Scient | Application d'oligonucleotides lies a un agent intercalant, notamment a titre de medicament |
JPS61103824A (ja) | 1984-10-27 | 1986-05-22 | Nippon Kayaku Co Ltd | ポリリボイノシン酸・ポリリボシチヂル酸・ポリ−レ−リジン複合体の注射用製剤の新規調製法 |
US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
US4833251A (en) | 1985-06-25 | 1989-05-23 | Siska Diagnostics, Inc. | Compounds for tagging nucleic acid probes |
US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
US5258538A (en) | 1985-08-26 | 1993-11-02 | Applied Biosystems, Inc. | 2,3-disubstituted-1,3,2-oxazaphosphacycloalkanes as nucleic acid linking agents |
US4868105A (en) | 1985-12-11 | 1989-09-19 | Chiron Corporation | Solution phase nucleic acid sandwich assay |
US4855225A (en) | 1986-02-07 | 1989-08-08 | Applied Biosystems, Inc. | Method of detecting electrophoretically separated oligonucleotides |
US5212059A (en) | 1988-01-11 | 1993-05-18 | Microprobe Corporation | Oligonucleotide probes for the detection of periodontal pathogens |
US5366860A (en) | 1989-09-29 | 1994-11-22 | Applied Biosystems, Inc. | Spectrally resolvable rhodamine dyes for nucleic acid sequence determination |
US5811232A (en) | 1989-12-04 | 1998-09-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides for Papillomavirus |
CA2078659A1 (fr) | 1990-03-21 | 1991-09-22 | David J. Ecker | Reactifs imitant iarn et methodes servant a la regulation de l'expresssion des genes |
US5874564A (en) | 1990-03-21 | 1999-02-23 | Isis Pharmaceuticals, Inc. | Reagents and methods for modulating gene expression through RNA mimicry |
US5665710A (en) | 1990-04-30 | 1997-09-09 | Georgetown University | Method of making liposomal oligodeoxynucleotide compositions |
US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
BR9106702A (pt) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals Inc | Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo |
BR9106751A (pt) | 1990-08-16 | 1993-08-17 | Isis Pharmaceuticals Ind | Oligonucleotideo ou analogo de nucleotideo e processo para modulacao da atividade de uma infeccao por citomegalovirus |
US5162654A (en) | 1991-02-01 | 1992-11-10 | Wisconsin Alumni Research Foundation | Detection apparatus for electrophoretic gels |
US5242906A (en) | 1991-04-22 | 1993-09-07 | University Of North Carolina At Chapel Hill | Antisense oligonucleotides against Epstein-Barr virus |
DE69214243T2 (de) | 1991-09-23 | 1997-02-06 | Pfizer | Verfahren für die Detektion von spezifische mRNS und DNS in Zellen |
US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
US5643780A (en) | 1992-04-03 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA |
US6303297B1 (en) | 1992-07-17 | 2001-10-16 | Incyte Pharmaceuticals, Inc. | Database for storage and analysis of full-length sequences |
US5541311A (en) | 1992-12-07 | 1996-07-30 | Third Wave Technologies, Inc. | Nucleic acid encoding synthesis-deficient thermostable DNA polymerase |
JPH0793370A (ja) | 1993-09-27 | 1995-04-07 | Hitachi Device Eng Co Ltd | 遺伝子データベース検索システム |
US5980096A (en) | 1995-01-17 | 1999-11-09 | Intertech Ventures, Ltd. | Computer-based system, methods and graphical interface for information storage, modeling and stimulation of complex systems |
DE19508366C2 (de) | 1995-03-10 | 1998-01-29 | Evotec Biosystems Gmbh | Verfahren zum direkten Nachweisen weniger Nucleinsäurestränge |
EP0876510B1 (fr) | 1995-12-22 | 2008-05-07 | Dade Behring Marburg GmbH | Amplification et detection homogenes des acides nucleiques |
IL128124A0 (en) | 1996-08-02 | 1999-11-30 | Genesense Technologies Inc | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase |
US6189013B1 (en) | 1996-12-12 | 2001-02-13 | Incyte Genomics, Inc. | Project-based full length biomolecular sequence database |
US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
TW520297B (en) | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
US5966712A (en) | 1996-12-12 | 1999-10-12 | Incyte Pharmaceuticals, Inc. | Database and system for storing, comparing and displaying genomic information |
WO1999005591A2 (fr) | 1997-07-25 | 1999-02-04 | Affymetrix, Inc. | Procede et appareil d'obtention d'une base de donnees bioinformatique |
-
1983
- 1983-06-21 CA CA000430882A patent/CA1223831A/fr not_active Expired
- 1983-06-22 EP EP94105993A patent/EP0618228A1/fr not_active Withdrawn
- 1983-06-22 EP EP83106112A patent/EP0097373B1/fr not_active Expired - Lifetime
- 1983-06-22 ES ES523503A patent/ES8700270A1/es not_active Expired
- 1983-06-22 DE DE3382822T patent/DE3382822T2/de not_active Expired - Lifetime
- 1983-06-22 EP EP19880104965 patent/EP0302175A3/fr not_active Withdrawn
- 1983-06-22 DE DE8383106112T patent/DE3382626T2/de not_active Expired - Lifetime
- 1983-06-22 DE DE3382782T patent/DE3382782T2/de not_active Expired - Lifetime
- 1983-06-22 EP EP19880104964 patent/EP0285950A3/fr not_active Ceased
- 1983-06-22 AT AT88104963T patent/ATE165605T1/de not_active IP Right Cessation
- 1983-06-22 AT AT83106112T patent/ATE81342T1/de not_active IP Right Cessation
- 1983-06-22 IL IL69051A patent/IL69051A/xx unknown
- 1983-06-22 EP EP19880104962 patent/EP0285058A3/fr not_active Withdrawn
- 1983-06-22 EP EP88104963A patent/EP0286898B1/fr not_active Revoked
- 1983-06-22 AT AT88104961T patent/ATE119164T1/de not_active IP Right Cessation
- 1983-06-22 EP EP88104961A patent/EP0285057B1/fr not_active Revoked
- 1983-06-23 JP JP58113599A patent/JP2625095B2/ja not_active Expired - Lifetime
- 1983-06-23 AU AU16179/83A patent/AU585199B2/en not_active Ceased
- 1983-06-23 DK DK291183A patent/DK291183A/da not_active Application Discontinuation
- 1983-06-23 NO NO832292A patent/NO832292L/no unknown
-
1985
- 1985-01-02 ES ES539316A patent/ES8700324A1/es not_active Expired
- 1985-09-26 ES ES547320A patent/ES8606903A1/es not_active Expired
- 1985-09-26 ES ES547319A patent/ES8802257A1/es not_active Expired
-
1989
- 1989-09-15 AU AU41493/89A patent/AU4149389A/en not_active Abandoned
-
1993
- 1993-06-10 JP JP5177184A patent/JP2760466B2/ja not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/486,069 patent/US8097405B1/en active Active
- 1995-06-07 US US08/479,997 patent/US6992180B1/en not_active Expired - Lifetime
-
1997
- 1997-10-28 JP JP29588997A patent/JP3170235B2/ja not_active Expired - Lifetime
-
1999
- 1999-01-14 JP JP11008415A patent/JPH11292892A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO832292L (no) | Modifiserte merkede nukleotider og polynukleotider samt deres fremstilling, anvendelse og paavisning | |
EP0063879B1 (fr) | Nucléotides modifiés et méthode pour leur préparation et leur utilisation | |
US5449767A (en) | Modified polynucleotides and methods of preparing same | |
US5260433A (en) | Saccharide specific binding system labeled nucleotides | |
US5241060A (en) | Base moiety-labeled detectable nucleatide | |
US5763167A (en) | Applications of fluorescent N-nucleosides and fluorescent structural analogs of N-nucleosides | |
EP0329198B1 (fr) | Oligonucléotides et polynucléotides modifiés à bases et méthodes pour la preparation et l'utilisation des mêmes | |
US8053212B1 (en) | Non-standard nucleoside analogs with reduced epimerization | |
JP4898119B2 (ja) | 検出できるラベルされたヌクレオシド類似体及びその使用方法 | |
JP2001503742A (ja) | ヌクレオチドを標識付けする方法、標識ヌクレオチド及び有用な中間体 | |
US7220854B1 (en) | Sugar moiety labeled nucleotide, and an oligo- or polynucleotide, and other compositions comprising such sugar moiety labeled nucleotides | |
WO2004037989A2 (fr) | Nucleotides modifies et procedes de marquage d'acides nucleiques |